Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden
Viktor Molander, Hannah Bower, Thomas Frisell, et al.
Annals of the Rheumatic Diseases (2020) Vol. 80, Iss. 2, pp. 169-175
Open Access | Times Cited: 94

Showing 26-50 of 94 citing articles:

Extra-Articular Manifestations and Comorbidities in Psoriatic Disease: A Journey Into the Immunologic Crosstalk
Lucia Novelli, Ennio Lubrano, Vincenzo Venerito, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 26
Validation and characterization of venous thromboembolism diagnoses in the Swedish National Patient Register among patients with rheumatoid arthritis
Viktor Molander, Hannah Bower, Johan Askling
Scandinavian Journal of Rheumatology (2022) Vol. 52, Iss. 2, pp. 111-117
Open Access | Times Cited: 18
Medication adherence in rheumatoid arthritis: implications for cardiovascular disease risk and strategies to address in U.S. Veterans
Isaac D. Smith, Bryant R. England, Neha J. Pagidipati, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2025)
Closed Access
Eltrombopag for the treatment of refractory connective tissue disease-related thrombocytopenia: a pilot study of 52 cases
Siying Deng, Bei Wang, Ziwei Hu, et al.
Arthritis Research & Therapy (2025) Vol. 27, Iss. 1
Open Access
Do newly approved drugs have a worse observed safety profile than once established? A study on time trends in risks of key safety outcomes with immunomodulatory drugs against rheumatoid arthritis
Viktor Molander, Hannah Bower, Thomas Frisell, et al.
Annals of the Rheumatic Diseases (2025)
Open Access
Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update
Peter Nash, Andreas Kerschbaumer, Victoria Konzett, et al.
Annals of the Rheumatic Diseases (2025)
Open Access
Venous thromboembolic events in patients treated with Janus kinase inhibitors for atopic dermatitis
C. Droitcourt, Sandrine Kerbrat, D. Staumont‐Sallé, et al.
Journal of the European Academy of Dermatology and Venereology (2025)
Closed Access
Thrombotic Markers in Plasma as Predictors of Response in Rheumatoid Arthritis Patients Treated with Baricitinib – Pilot Observation
Anna Felis-Giemza, Kornelia Chmurzyńska, Jakub Wroński, et al.
Archivum Immunologiae et Therapiae Experimentalis (2025) Vol. 73, Iss. 1
Closed Access
How JAK inhibitors tip the prothrombotic balance in rheumatoid arthritis
Vibeke Strand
Nature Reviews Rheumatology (2025)
Closed Access
Recent issues in JAK inhibitor safety: perspective for the clinician
R. Fleischmann
Expert Review of Clinical Immunology (2022) Vol. 18, Iss. 3, pp. 295-307
Closed Access | Times Cited: 16
Venous thromboembolism risk is lower in patients with atopic dermatitis than other immune-mediated inflammatory diseases: A retrospective, observational, comparative cohort study using US claims data
Joseph F. Merola, Brennan Ertmer, Huifang Liang, et al.
Journal of the American Academy of Dermatology (2023) Vol. 90, Iss. 5, pp. 935-944
Open Access | Times Cited: 9
Artificial Intelligence in the Diagnosis and Treatment of Rheumatoid Arthritis: Current Status and Future Prospects
Fatima Nazish Khan, Mohammad Asim, Mohammad Irfan Qureshi
Studies in computational intelligence (2024), pp. 193-221
Closed Access | Times Cited: 3
Risk factors for venous thromboembolism and atherosclerotic cardiovascular disease: do they differ in patients with rheumatoid arthritis?
Gülşen Özen, Sofia Pedro, Rebecca Schumacher, et al.
RMD Open (2021) Vol. 7, Iss. 2, pp. e001618-e001618
Open Access | Times Cited: 20
Disease activity as a risk factor for venous thromboembolism in rheumatoid arthritis analysed using time-averaged DAS28CRP: a nested case–control study
Masaru Yoshimura, Yuichiro Fujieda, M. Sugawara, et al.
Rheumatology International (2022) Vol. 42, Iss. 11, pp. 1939-1946
Closed Access | Times Cited: 14
Building a better NET: Neutrophil extracellular trap targeted therapeutics in the treatment of infectious and inflammatory disorders
Anh T. P. Ngo, Kandace Gollomp
Research and Practice in Thrombosis and Haemostasis (2022) Vol. 6, Iss. 7, pp. e12808-e12808
Open Access | Times Cited: 14
Venous Thromboembolism in Rheumatoid Arthritis: The Added Effect of Disease Activity to Traditional Risk Factors
Mohammed A. Omair, Sara A Alkhelb, Sadeen E Ezzat, et al.
Open Access Rheumatology Research and Reviews (2022) Vol. Volume 14, pp. 231-242
Open Access | Times Cited: 12
Disease-modifying anti-rheumatic drugs improve the cardiovascular profile in patients with rheumatoid arthritis
Andrea Giachi, Massimo Cugno, Roberta Gualtierotti
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 12
Clinical disease activity is a major determinant of plasma D-dimer elevation in outpatients with rheumatoid arthritis: A hospital-based cross-sectional study
Shunsuke Mori, Hirofumi Soejima, Jun Hokamaki, et al.
Modern Rheumatology (2023) Vol. 34, Iss. 2, pp. 313-321
Open Access | Times Cited: 7
Pharmacologic Anticoagulation Is Associated With a Lower Risk of Recurrent Venous Thromboembolic Events During Janus Kinase Inhibitor Use for Patients With a Prior Thrombosis
Jeffrey A. Lowell, G.V.R.K. Sharma, Arun Swaminath, et al.
Inflammatory Bowel Diseases (2024)
Closed Access | Times Cited: 2
A systematic review and meta‐analysis of the association between the D‐dimer and rheumatic diseases
Angelo Zinellu, Arduino A. Mangoni
Immunity Inflammation and Disease (2024) Vol. 12, Iss. 7
Open Access | Times Cited: 2
Role of Janus Kinase inhibitors in rheumatoid arthritis treatment
Virginia Reddy, Stanley Cohen
Current Opinion in Rheumatology (2021) Vol. 33, Iss. 3, pp. 300-306
Closed Access | Times Cited: 16
Risk of venous thromboembolism in Korean patients with rheumatoid arthritis treated with Janus kinase inhibitors: A nationwide population-based study
Yeo‐Jin Song, Soo‐Kyung Cho, Jeongyeon Kim, et al.
Seminars in Arthritis and Rheumatism (2023) Vol. 61, pp. 152214-152214
Closed Access | Times Cited: 6
Validation of an Algorithm to Identify Venous Thromboembolism in Health Insurance Claims Data Among Patients with Rheumatoid Arthritis
Sangmi Kim, Carolyn Martin, John White, et al.
Clinical Epidemiology (2023) Vol. Volume 15, pp. 671-682
Open Access | Times Cited: 6
Increased Risk of Cardiovascular Diseases in Rheumatoid Arthritis: A Systematic Review
Hadi Farhat, Huma Irfan, Kanmani Muthiah, et al.
Cureus (2022)
Open Access | Times Cited: 10
Risk of venous thromboembolism associated with methotrexate versus hydroxychloroquine for rheumatoid arthritis: A propensity score-matched cohort study
Mengdong He, Ajinkya Pawar, Rishi Desai, et al.
Seminars in Arthritis and Rheumatism (2021) Vol. 51, Iss. 6, pp. 1242-1250
Closed Access | Times Cited: 12

Scroll to top